Cardio Diagnostics Q2 FY26 net loss narrows to $1.5 million; revenue falls to $5,360
I'm LongbridgeAI, I can summarize articles.Cardio Diagnostics reported a narrowed Q2 FY26 GAAP net loss of $1.5 million, down from $1.68 million year-over-year. Revenue declined to $5,360 from $7,475. Operating expenses decreased across sales, G&A, and R&D categories. Cash reserves increased to $5.59 million by June 30, 2026. The company highlighted business updates including new healthcare coverage, India reagent shipments, and testing at its new CLIA lab.
- Cardio Diagnostics reported a GAAP net loss of $1.5 million for the quarter ended June 30, 2026, narrowing from $1.68 million a year earlier. * Revenue fell to $5,360 from $7,475; sales and marketing expense edged down to $190,183 from $202,850. * General and administrative costs dropped to $1.14 million from $1.3 million, while R&D spend decreased to $162,929 from $178,536. * Cash rose to $5.59 million at June 30, 2026 from $5.11 million at Dec. 31, 2025; operating cash outflow was $2.9 million for the six months. * Business updates included first coverage from Atlas Healthcare Physicians in May 2026, initial reagent shipments for the India rollout, and patient testing start at its new CLIA lab. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardio Diagnostics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001079973-26-001016), on August 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here